Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $211.65 | Total: $1,058.25 |
| 1 | 10 | $179.28 | Total: $1,792.80 |
| 1 | 25 | $151.89 | Total: $3,797.25 |
| 1 | 50 | $129.48 | Total: $6,474.00 |
| 1 | 100 | $112.05 | Total: $11,205.00 |
Overview
ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells.
Chemical Properties
| Molecular Formula | C22H16F4N4O3S |
| Molecular Weight | 492.45 |
| CAS Numbers | 1351185-54-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1[C@@]2(N(C(=S)N1C3=CC(C(F)(F)F)=C(C#N)C=C3)C4=CC(F)=C(C(NC)=O)C=C4)CCOC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Ivachtchenko AV, et al. Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5[2] 133-42.